IL2 and bacterial infectious disease: Moreover, low-dose IL-2 treatment in SLE patients has been previously shown to lead to a threefold reduction in the incidence of both viral and bacterial infection [33], potentially reflecting the prolonged heightened anti-inflammatory state in these patients.